Pfizer Sales Fall Short as Pressure Mounts to Make a Deal

Pfizer Sales Fall Short as Pressure Mounts to Make a Deal


Investors are watching Pfizer's next move after several quarters of lackluster results, dragged down by its top-selling Prevnar vaccination shots and sales of products that are facing loss of exclusivity, like the erectile dysfunction treatment Viagra. Newer drugs, like blockbuster breast cancer drug Ibrance, showed strength last quarter, but it wasn't enough to lift overall sales.



from Biotech News